Advanced Practice Perspectives on CDK 4/6 Inhibitors: Paving the Way for HR+, HER2-Negative Early Breast Cancer - a podcast by ReachMD

CME credits: 1.00

Valid until: 26-07-2022

Claim your CME credit at https://reachmd.com/programs/cme/advanced-practice-perspectives-cdk-46-inhibitors-paving-way-hr-her2-negative-early-breast-cancer/12698/

Endocrine therapy is currently the cornerstone of treatment for advanced hormone receptor–positive (HR+) breast cancer in both pre- and postmenopausal patients. However, not all advanced HR+ breast cancers respond to first-line endocrine therapy, and those that do respond eventually relapse. Agents that target critical pathways involved in resistance to endocrine therapy, such as cyclin-dependent kinase (CDK) 4/6 inhibitors, have been approved by the US Food & Drug Administration (FDA) for the treatment of HR+/human epidermal growth factor receptor 2–negative (HER2?) advanced/metastatic breast cancer. Now, CDK 4/6 inhibitors are being investigated for the treatment of early stage HR+, HER2- breast cancer.
This web-based, on-demand, activity will feature interprofessional perspectives and expert insights on the latest emerging evidence for CDK 4/6 inhibitors in the adjuvant setting for early breast cancer. The faculty panel will also provide their perspectives and best practice recommendations for improving adherence and side effect management. Case-based discussion will provide practical approaches for integrating CDK 4/6 inhibitors into real-world clinical practice for the treatment of early stage HR+, HER2- breast cancer.

Since the date of this activity’s recording, an exciting and practice changing advancement has occurred with the Food and Drug Administration’s (FDA) recent approval of abemaciclib with endocrine ...